Stabilized KP-10 Analogs

Stabilized Kp-10 Analogs

KP10

Peptide Therapeutics

Rationally modified derivatives of kisspeptin-10 (KP-10), based on the native sequence YNWSFGLRF-NH2, may retain KISS1R receptor agonism while demonstrating improved metabolic stability and longer systemic exposure.

Description

Team

Vladimir Demidov

Research Lead

Organisation

Molecule

Experiment Cost

$0.00

Project Score

Technology Readiness Level

PRE-TRL

TRL 1

TRL 2

TRL 3

TRL 4

Hypothesis formulated

Basic principles observed

Technology concept formulated

Experimental proof of concept

Technology validated in lab

Rationale

Project is explicitly pre-experimental with no wet-lab or computational validation conducted. All analog designs, stability profiles, and efficacy claims are hypothetical, with experiments only…

Assessment

Low Confidence

ProgressHIGH

Total Score3.75

Overall Assessment

This TRL 1 project presents a scientifically sound hypothesis grounded in validated KISS1R biology and well-characterized KP-10 degradation mechanisms, earning strong therapeutic relevance. Broad applicability across fertility, oncology, endocrinology, and metabolism provides good optionality. The main gap is IP: while three distinct analog classes (N-terminal protection, cleavage-site hardening, conformational locking) offer differentiation potential, kisspeptin analog space is competitive with known prior art. No experimental data exist yet—all scores reflect conceptual strength only.…

Weighted Score

Project Progress

All updates

All categories

Timeline